| Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies (NCT05316701) | Orca Biosystems, Inc. | 2022-06-21 |
| Latin American Real-world Study in Acute Leukemia (NCT05166135) | Pfizer | 2021-12-10 |
| Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy (NCT04778579) | Sara V. Latorre | 2021-05-11 |
| HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation (NCT04464889) | Medigene AG | 2020-07-02 |
| Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies (NCT04013685) | Orca Biosystems, Inc. | 2019-11-21 |
| Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia (NCT03610438) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2019-10-30 |
| A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) (NCT03833180) | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2019-03-14 |
| CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies (NCT03448393) | National Cancer Institute (NCI) | 2018-03-26 |
| G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor (NCT02933333) | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 2016-09-27 |
| Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery (NCT02767388) | University of Nebraska | 2016-09-01 |
| The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens (NCT02413021) | Isfahan University of Medical Sciences | 2016-05-01 |
| The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents (NCT02953730) | Chinese Academy of Medical Sciences | 2015-09-01 |
| iCare for Cancer Patients (NCT02435550) | University of Florida | 2015-06-26 |
| Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation (NCT02458235) | University of California, San Francisco | 2015-06-02 |
| Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies (NCT02419755) | St. Jude Children's Research Hospital | 2015-04-14 |
| Evaluation of Adverse Long-term Effects in Young Adult Survivors of Acute Leukemia (NCT02345915) | Institut Paoli-Calmettes | 2014-11-01 |
| Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT (NCT02294552) | Ivan S Moiseev | 2014-10-01 |
| Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission (NCT02605460) | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 2014-02-01 |
| Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT (NCT03977103) | University Of Perugia | 2014-02-01 |
| Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis (NCT01749111) | Hospital Israelita Albert Einstein | 2012-12-01 |
| Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant (NCT01720264) | Sherif S. Farag | 2012-11-02 |
| Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies (NCT01461538) | Seagen Inc. | 2011-10-01 |
| Phase I Study of OPB-51602 in Patients With Hematologic Malignancies (NCT01344876) | Otsuka Pharmaceutical Co., Ltd. | 2011-04-01 |
| Donor-specific Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) (NCT01037764) | Asan Medical Center | 2010-01-01 |
| Efficacy and Safety of Recombinant Asparaginase in Infants With Previously Untreated Acute Lymphoid Leukemia (ALL) (NCT00983138) | medac GmbH | 2009-07-01 |
| Erwinase Master Treatment Protocol (NCT00590915) | Phoenix Children's Hospital | |
| Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies (NCT07346105) | Orca Biosystems, Inc. | |